

**II. Claim Amendments**

Claim 1 (Cancelled, without prejudice or disclaimer)

2. A peptide consisting of 16 to 55 amino acid residues, comprising the amino acid sequence YKLVCYYTWSWSQYREG (SEQ ID NO: 1).

Claims 3-6 (Cancelled, without prejudice or disclaimer)

7. A pharmaceutical composition comprising a peptide according to claim 2, and a pharmaceutically acceptable carrier.

Claims 8-10 (Cancelled without prejudice or disclaimer)

11. A test kit for use in the detection of activated autoreactive T cells, comprising a peptide according to claim 2.

Claim 12 (Cancelled, without prejudice or disclaimer)

13. A pharmaceutical composition consisting of one or more peptides selected from the group consisting of peptides [containing] consisting of 16 to 55 amino acid residues and comprising the amino acid sequence YKLVCYYTWSWSQYREG (SEQ ID NO: 1).

14. A pharmaceutical composition consisting of one or more peptides selected from the group consisting of peptides [containing] consisting of 16 to 55 amino acid residues and comprising the amino acid sequence YKLVCYYTWSWSQYREG (SEQ ID NO: 1).

15. A method of inducing systemic immunological tolerance, comprising administering to a patient in need thereof a pharmaceutical composition comprising one

2

or more peptides containing 16 to 55 amino acid residues selected from the group consisting of the amino acid sequence LVCYYTWSWS (SEQ ID NO: 60) and a pharmaceutically acceptable carrier.

16. A method for inducing a systemic immunological tolerance, comprising administering to a patient in need thereof a pharmaceutical composition according to claim 13.
17. A method for inducing a systemic immunological tolerance, comprising administering to a patient in need thereof a pharmaceutical composition according to claim 14.

3